BOGOTA, Colombia – A panel of experts is raising concerns about spotty access to biologics – and eventually biosimilars – across Latin America to treat multiple sclerosis (MS). Their concerns are linked to patient access, pricing, regulations and reporting, and also stem, in part, from the fragmented nature of the continent. Latin America has a population of 626 million scattered across 33 different markets with just as many regulatory structures.